Stool test

Verséa Health, Inc. Launches Verséa Easy Lab™, Affordable, Highly Accurate Over-the-Counter (OTC) Product Line

Retrieved on: 
Tuesday, August 15, 2023
Health, FDA, Medical Devices, General Health, Research, Science, Pharmaceutical, Ovulation, Pregnancy, Therapy, Stool test, Aetna Health Inc. v. Davila

Verséa Health, Inc. (“ Verséa ”), a Florida-based health care company engaged in the commercialization of innovative diagnostics and therapeutics, has launched the Verséa Easy Lab™ product line of rapid, at-home, over-the-counter diagnostic tests that will be sold at retail locations nationwide.

Key Points: 
  • Verséa Health, Inc. (“ Verséa ”), a Florida-based health care company engaged in the commercialization of innovative diagnostics and therapeutics, has launched the Verséa Easy Lab™ product line of rapid, at-home, over-the-counter diagnostic tests that will be sold at retail locations nationwide.
  • The affordable, FDA approved, and professional quality tests will enable people to check up on their health at any time and in the comfort of their homes.
  • James Olin, Chief Commercial Officer at Verséa Health, Inc. explained the reason behind the launch: “The Verséa Easy Lab™ product line was created with a mission to give millions of Americans direct access to the most essential and necessary health care services with an emphasis on prediction, prevention, and value.
  • This launch also strategically fits with our focus on supporting new and more accessible locations of care like urgent care clinics and independent community pharmacies.”
    To learn more about Verséa Health, Inc. and the Verséa Easy Lab™ product line, visit the Verséa Health webpage or contact directly at [email protected] or 1-800-397-0670

Microba Launches Next Generation Healthcare Testing

Retrieved on: 
Tuesday, February 28, 2023
Medical Supplies, Biotechnology, Health, General Health, Pharmaceutical, Other Science, Medical Devices, Research, Infectious Diseases, Science, Clinical Trials, Parasitism, Bacteria, Cyclospora cayetanensis, Yersinia enterocolitica, Annual report, Lactoferrin, Fungus, Butyric acid, Methane, ASX, File association, Lipopolysaccharide, Giardia duodenalis, Immunoglobulin A, Health professional, TMA, Pancreatic elastase, Stool test, Entamoeba histolytica, Microorganism, Completeness, IPA, BCAA, Multimedia, MAP, Diagnosis, Pharmaceutical industry, Antibiotics, Blastocystis

Microba Life Sciences Limited (ASX: MAP) (“Microba”), a precision microbiome company, is pleased to announce that it’s next generation testing product range, MetaXplore™ has been launched to healthcare professionals in Australia under a new brand, Co-Biome™.

Key Points: 
  • Microba Life Sciences Limited (ASX: MAP) (“Microba”), a precision microbiome company, is pleased to announce that it’s next generation testing product range, MetaXplore™ has been launched to healthcare professionals in Australia under a new brand, Co-Biome™.
  • The MetaXplore™ test range has been developed together with healthcare professionals and brought to market under a new brand called Co-Biome™.
  • The MetaXplore™ test range through Co-Biome™ represents an important step forward in that strategy by breaking new ground in the application of microbiome testing in healthcare.
  • Microba’s Chief Scientific Officer, Assoc Prof. Lutz Krause said, “These new tests integrate traditional gastrointestinal pathology tools with Microba’s next generation microbiome testing technology and the latest global research to significantly advance the utility of microbiome testing in a healthcare setting.

ProciseDx Achieves CE Mark for Fecal Calprotectin Point of Care Testing

Retrieved on: 
Tuesday, February 23, 2021
Medical specialties, Clinical medicine, Medicine, Autoimmune diseases, Diarrhea, Abdominal pain, Diagnostic gastroenterology, Faecal calprotectin, Colitis, Ulcerative colitis, Crohn's disease, Stool test

SAN DIEGO, Feb. 23, 2021 /PRNewswire/ --ProciseDx Inc. announced today that it has received CE mark for its Fecal Calprotectin (Procise FCP) point of care tests for use on the ProciseDx system.

Key Points: 
  • SAN DIEGO, Feb. 23, 2021 /PRNewswire/ --ProciseDx Inc. announced today that it has received CE mark for its Fecal Calprotectin (Procise FCP) point of care tests for use on the ProciseDx system.
  • Offering a point of care test for fecal calprotectin will help many physicians expedite their diagnosis of Crohn's Disease or Ulcerative Colitis, as well as other digestive conditions.
  • Typically, a patient must provide a stool sample in a large container and deliver it to their doctor's office or laboratory.
  • So, the ProciseDx platform empowers the gastroenterology community to start delivering true point of care solutions to their patients."

Geneoscopy Announces Positive Results of Colorectal Cancer Screening Test in Prospective, Multicenter Clinical Study

Retrieved on: 
Thursday, November 19, 2020
Oncology, Health, Other Science, Clinical trials, Research, Science, Biotechnology, Medicine, Clinical medicine, Health, Cancer screening, Large intestine, Diagnostic gastroenterology, Colorectal cancer, Stool test, Adenoma, Cancer, Screening, Colonoscopy, Colorectal Cancer, Geneoscopy Inc.

Geneoscopy Inc., a life sciences company that develops diagnostic tests for gastrointestinal health, today announced positive results of their diagnostic in detecting both colorectal cancer and precancerous adenomas in a large, multicenter prospective study.

Key Points: 
  • Geneoscopy Inc., a life sciences company that develops diagnostic tests for gastrointestinal health, today announced positive results of their diagnostic in detecting both colorectal cancer and precancerous adenomas in a large, multicenter prospective study.
  • In particular, the observed detection rate of advanced adenomas offers novel capabilities for preventing the development of colorectal cancer, the second deadliest cancer in the United States.
  • The prospective, multicenter clinical study used digital platforms to virtually recruit and enroll 1,305 participants who provided a stool sample to Geneoscopy prior to receiving a screening colonoscopy.
  • To supplement the prospective cohort, Geneoscopy also assessed a retrospective cohort of patients previously diagnosed with colorectal cancer.

Global GI Stool Testing Markets, 2020-2025: Reagent Segment is Expected to Hold a Major Market Share

Retrieved on: 
Monday, November 9, 2020
Medical specialties, Feces, Clinical medicine, Waterborne diseases, Sanitation, Gastroenterology, Sustainable Development Goal 6, Diarrhea, Stool test, Mergers and acquisitions

Reagents are expected to dominate the GI stool testing market with developing diagnostic technology.

Key Points: 
  • Reagents are expected to dominate the GI stool testing market with developing diagnostic technology.
  • Furthermore, the rising prevalence of diarrhea is expected to raise the demand for reagents in the GI stool testing market.
  • Hence, it is expected to influence the GI stool testing market growth positively in this segment.
  • Collaborations, mergers, and acquisitions by companies related to GI stool testing are expected to boost the market growth.

Global GI Stool Testing Markets, 2020-2025: Growth, Trends, and Forecasts - Rising Demand for Point of Care Tests Expected to Fuel Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, November 3, 2020
Health, General Health, Medical specialties, Digestive diseases, Clinical medicine, Feces, Waterborne diseases, Sanitation, Diarrhea, Stool test, Gastrointestinal tract, Strongyloidiasis, Fecal microbiota transplant

The increasing burden of diseases related to the gastrointestinal tract and rising demand for point of care tests is expected to fuel the GI stool testing market growth.

Key Points: 
  • The increasing burden of diseases related to the gastrointestinal tract and rising demand for point of care tests is expected to fuel the GI stool testing market growth.
  • Thus, this factor can increase the demand for GI stool testing to detect bacteria and parasites.
  • Furthermore, the rising prevalence of diarrhea is expected to raise the demand for reagents in the GI stool testing market.
  • Collaborations, mergers, and acquisitions by companies related to GI stool testing are expected to boost the market growth.

Freenome Announces Encouraging Performance Data for Its Multiomics Blood Test to Detect Early-Stage Colorectal Cancer in a Prospective, Multi-Center Clinical Study

Retrieved on: 
Thursday, January 23, 2020
Oncology, Health, Technology, Other Technology, General Health, Clinical trials, Biotechnology, Medicine, Clinical medicine, Health, Diagnostic gastroenterology, Oncology, Cheminformatics, Sensitivity and specificity, Statistical classification, Colorectal cancer, Sampling, Stool test, Fecal occult blood, Colorectal Cancer and AI-EMERGE, Freenome

Subjects enrolled in the study were asked to provide both a blood and stool sample for a head-to-head comparison.

Key Points: 
  • Subjects enrolled in the study were asked to provide both a blood and stool sample for a head-to-head comparison.
  • In subjects with paired blood and stool samples, Freenomes multiomics blood test demonstrated 100% sensitivity and 96% specificity for CRC, whereas FIT achieved 67% sensitivity and 96% specificity.
  • AI-EMERGE is a clinical study that will advance the development of a blood-based test to detect colorectal cancer early.
  • Freenome is a biotechnology company that has pioneered a comprehensive multiomics platform for early cancer detection through a routine blood draw.

Green Bay Packers and Cologuard Launch "Crossing the 50" Colon Cancer Awareness Campaign

Retrieved on: 
Monday, August 13, 2018
Cancer, RTT, Medicine, Health, Exact Sciences, Pro Football Hall of Fame inductees, Cancer screening, Colorectal cancer, Precancerous condition, Vince Lombardi, Green Bay Packers, Stool test

Cologuard donates $50 to the Vince Lombardi Cancer Foundation each time the Green Bay Packers cross the 50-yard line this season.

Key Points: 
  • Cologuard donates $50 to the Vince Lombardi Cancer Foundation each time the Green Bay Packers cross the 50-yard line this season.
  • Exact Sciences, the manufacturer of Cologuard , and the Packers today announced the organizations are teaming up for the second consecutive season to promote colorectal (colon) cancer awareness and they've added the "Crossing the 50" campaign.
  • Cologuard is the only noninvasive colon cancer screening option for average risk adults that uses the DNA found in a person's stool sample to detect cancer and precancerous growths.
  • "The Green Bay Packers share Exact Sciences' vision for beating cancer through early detection," said Chad Watson, director of Sales and Business Development for the Green Bay Packers.

CellMax Life Launches Zenith, a U.S. Clinical Study for the Advancement of Blood Tests for Early Cancer Detection, With the Goal of Seeking FDA Approval

Retrieved on: 
Wednesday, May 30, 2018
Medicine, Clinical medicine, Cancer, RTT, Infectious causes of cancer, Cancer screening, Diagnostic gastroenterology, Medical terminology, Stool test, Colorectal cancer, Colonoscopy, Prostate cancer

In this study, thousands of patients coming in for routine colorectal cancer screening via colonoscopy or stool tests will be offered CellMax Life's blood test.

Key Points: 
  • In this study, thousands of patients coming in for routine colorectal cancer screening via colonoscopy or stool tests will be offered CellMax Life's blood test.
  • The results of the blood test will be compared to those from the colonoscopy and stool tests.
  • "We plan to work closely with the FDA upfront to define the details of this study," said Atul Sharan, CEO of CellMax Life.
  • CellMax Life's tests include CellMax-DNAHereditary Cancer Risk Test,CellMax-CRCColorectal Cancer Screening Test, CellMax-Prostate Cancer Test, CellMax-LBxLiquid Biopsy for immunotherapy and targeted therapy selection and CellMax-PanCa Monitoring Test.